Shares hike for Orthofix after positive quarter
This article was originally published in Clinica
Revenue growth of 6% helped Orthofix International record its highest share price in more than a year. The McKinney, Texas-based company saw shares reach $30.47 during trading on July 31, the company’s best pricing since June 2008. Revenues for the period were $137.5m, helped by a 13% growth in revenue from Orthofix’s spinal products business, to $70.7m. The firm’s CEO Alan Milinazzo attributed the good performance from the spine business to the recent launches of the Firebird pedicle screw system, the Pillar SA interbody device and the Trinity Evolution stem cell-based allograft. The company’s bottom line improved slightly from $5.8m to $5.9m.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals